Tropical spastic paraparesis primary prevention

Jump to navigation Jump to search

Tropical spastic paraparesis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tropical spastic paraparesis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tropical spastic paraparesis primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tropical spastic paraparesis primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tropical spastic paraparesis primary prevention

CDC on Tropical spastic paraparesis primary prevention

Tropical spastic paraparesis primary prevention in the news

Blogs on Tropical spastic paraparesis primary prevention

Directions to Hospitals Treating Tropical spastic paraparesis

Risk calculators and risk factors for Tropical spastic paraparesis primary prevention

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Blood transfusion products are screened for HTLV-1 antibodies.

References

Template:WH Template:WS